B+
Bull case
25%
Probability
Target price
$18.00
+75.4% vs current
OMER
OmerosDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$11.00
+7.2% vs current
B-
Bear case
25%
Probability
Target price
$6.00
-41.5% vs current
AI sentiment snapshot
Latest data as of 2026-04-15
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+61.1
Score
AI commentary
Sentiment should be treated as cautious-to-constructive, not outright bullish. The March 31, 2026 print improved the story by showing FDA approval, launch initiation, $240 million of upfront Novo cash, debt reduction and management's view that current resources can fund more than 12 months of operations [#8-K-2026-03-31] [#10-K-2026-03-31]. But the stock now needs proof of YARTEMLEA adoption; Q4 profitability was heavily shaped by the zaltenibart transaction, and the deterministic prior remains neutral with slightly negative forward returns, so this is better framed as a monitoring setup than a high-conviction rerating call.
RankAlpha Sentiment Codex - 2026-04-15
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-30catalystFirst reported YARTEMLEA launch metricsHigh impact
YARTEMLEA commercial distribution began in January 2026, and management said both adult and pediatric patients are already being treated across hospital and outpatient settings; the next financial update should be the first real test of demand, access and center adoption rather than approval optics [#8-K-2026-03-31] [#10-K-2026-03-31].
2026-07-15eventEMA decision on YARTEMLEA TA-TMA filingHigh impact
Omeros said the EMA is reviewing the YARTEMLEA marketing authorization application and the March 31, 2026 earnings release said a decision is expected in mid-2026; approval would open the EU/EEA market, while delay or rejection would weaken the current post-approval narrative [#10-K-2026-03-31] [#8-K-2026-03-31].
2026-12-31catalystRunway and financing overhang re-rate if launch traction holdsHigh impact
The company ended 2025 with $171.8 million of cash and short-term investments, repaid the remaining 2026 converts in February 2026, and said it expects to fund more than 12 months of operations from existing resources plus YARTEMLEA sales; if that proves true, financing pressure should fade, but weak launch data could push investors back toward ATM and other capital-raise scenarios [#10-K-2026-03-31].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-15 • Updated nightlySource: Internal modelMethodology